Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

For: Salaffi F, Di Carlo M, Carotti M, Sarzi-Puttini P. The Effect of Neuropathic Pain Symptoms on Remission in Patients with Early Rheumatoid Arthritis. Curr Rheumatol Rev 2019;15:154-161. [PMID: 30081788 DOI: 10.2174/1573397114666180806142814] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2018] [Revised: 07/02/2018] [Accepted: 07/17/2018] [Indexed: 01/08/2023]

For:	Salaffi F, Di Carlo M, Carotti M, Sarzi-Puttini P. The Effect of Neuropathic Pain Symptoms on Remission in Patients with Early Rheumatoid Arthritis. Curr Rheumatol Rev 2019;15:154-161. [PMID: 30081788 DOI: 10.2174/1573397114666180806142814] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2018] [Revised: 07/02/2018] [Accepted: 07/17/2018] [Indexed: 01/08/2023]

Number

Cited by Other Article(s)

Baerwald C, Stemmler E, Gnüchtel S, Jeromin K, Fritz B, Bernateck M, Adolf D, Taylor PC, Baron R. Predictors for severe persisting pain in rheumatoid arthritis are associated with pain origin and appraisal of pain. Ann Rheum Dis 2024;83:1381-1388. [PMID: 38816064 DOI: 10.1136/ard-2023-225414] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2023] [Accepted: 05/04/2024] [Indexed: 06/01/2024]

Bandinelli F, Nassini R, Gherardi E, Chiocchetti B, Manetti M, Cincotta M, Nozzoli F, Nucci E, De Logu F, Pimpinelli N. Small Fiber Neuropathy Associated with Post-COVID-19 and Post-COVID-19 Vaccination Arthritis: A Rare Post-Infective Syndrome or a New-Onset Disease? J Pers Med 2024;14:789. [PMID: 39201981 PMCID: PMC11355276 DOI: 10.3390/jpm14080789] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2024] [Revised: 07/12/2024] [Accepted: 07/23/2024] [Indexed: 09/03/2024] Open

Sarzi-Puttini P, Pellegrino G, Giorgi V, Bongiovanni SF, Varrassi G, Di Lascio S, Fornasari D, Sirotti S, Di Carlo M, Salaffi F. "Inflammatory or non-inflammatory pain in inflammatory arthritis - How to differentiate it?". Best Pract Res Clin Rheumatol 2024;38:101970. [PMID: 39004557 DOI: 10.1016/j.berh.2024.101970] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2024] [Accepted: 05/04/2024] [Indexed: 07/16/2024]

Marino A, Currado D, Altamura C, Vomero M, Berardicurti O, Corberi E, Kun L, Pilato A, Biaggi A, Genovali I, Bearzi P, Minerba M, Orlando A, Trunfio F, Quadrini M, Salvolini C, Di Corcia LP, Saracino F, Giacomelli R, Navarini L. Increased Prevalence of Headaches and Migraine in Patients with Psoriatic Arthritis and Axial Spondyloarthritis: Insights from an Italian Cohort Study. Biomedicines 2024;12:371. [PMID: 38397972 PMCID: PMC10886921 DOI: 10.3390/biomedicines12020371] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2023] [Revised: 12/14/2023] [Accepted: 01/12/2024] [Indexed: 02/25/2024] Open

Affiliation(s)

Annalisa Marino Rheumatology and Clinical Immunology, Department of Medicine, School of Medicine, University of Rome “Campus Bio-Medico”, 00128 Rome, Italy; (A.M.); (D.C.); (M.V.); (E.C.); (L.K.); (A.P.); (A.B.); (I.G.); (M.M.); (A.O.); (F.T.); (M.Q.); (C.S.); (L.P.D.C.); (F.S.); (R.G.); (L.N.) Clinical and Research Section of Rheumatology and Clinical Immunology, Fondazione Policlinico Universitario Campus Bio-Medico, 00128 Rome, Italy
Damiano Currado Rheumatology and Clinical Immunology, Department of Medicine, School of Medicine, University of Rome “Campus Bio-Medico”, 00128 Rome, Italy; (A.M.); (D.C.); (M.V.); (E.C.); (L.K.); (A.P.); (A.B.); (I.G.); (M.M.); (A.O.); (F.T.); (M.Q.); (C.S.); (L.P.D.C.); (F.S.); (R.G.); (L.N.) Clinical and Research Section of Rheumatology and Clinical Immunology, Fondazione Policlinico Universitario Campus Bio-Medico, 00128 Rome, Italy
Claudia Altamura Instituite of Neurology, Fondazione Policlinico Universitario Campus Bio-Medico, Via Alvaro del Portillo, 200, 00128 Rome, Italy; Unit of Headache and Neurosonology, Department of Medicine and Surgery, University of Rome “Campus Bio-Medico”, 00128 Rome, Italy
Marta Vomero Rheumatology and Clinical Immunology, Department of Medicine, School of Medicine, University of Rome “Campus Bio-Medico”, 00128 Rome, Italy; (A.M.); (D.C.); (M.V.); (E.C.); (L.K.); (A.P.); (A.B.); (I.G.); (M.M.); (A.O.); (F.T.); (M.Q.); (C.S.); (L.P.D.C.); (F.S.); (R.G.); (L.N.)
Onorina Berardicurti Rheumatology and Clinical Immunology, Department of Medicine, School of Medicine, University of Rome “Campus Bio-Medico”, 00128 Rome, Italy; (A.M.); (D.C.); (M.V.); (E.C.); (L.K.); (A.P.); (A.B.); (I.G.); (M.M.); (A.O.); (F.T.); (M.Q.); (C.S.); (L.P.D.C.); (F.S.); (R.G.); (L.N.) Clinical and Research Section of Rheumatology and Clinical Immunology, Fondazione Policlinico Universitario Campus Bio-Medico, 00128 Rome, Italy
Erika Corberi Rheumatology and Clinical Immunology, Department of Medicine, School of Medicine, University of Rome “Campus Bio-Medico”, 00128 Rome, Italy; (A.M.); (D.C.); (M.V.); (E.C.); (L.K.); (A.P.); (A.B.); (I.G.); (M.M.); (A.O.); (F.T.); (M.Q.); (C.S.); (L.P.D.C.); (F.S.); (R.G.); (L.N.)
Lyubomyra Kun Rheumatology and Clinical Immunology, Department of Medicine, School of Medicine, University of Rome “Campus Bio-Medico”, 00128 Rome, Italy; (A.M.); (D.C.); (M.V.); (E.C.); (L.K.); (A.P.); (A.B.); (I.G.); (M.M.); (A.O.); (F.T.); (M.Q.); (C.S.); (L.P.D.C.); (F.S.); (R.G.); (L.N.)
Andrea Pilato Rheumatology and Clinical Immunology, Department of Medicine, School of Medicine, University of Rome “Campus Bio-Medico”, 00128 Rome, Italy; (A.M.); (D.C.); (M.V.); (E.C.); (L.K.); (A.P.); (A.B.); (I.G.); (M.M.); (A.O.); (F.T.); (M.Q.); (C.S.); (L.P.D.C.); (F.S.); (R.G.); (L.N.)
Alice Biaggi Rheumatology and Clinical Immunology, Department of Medicine, School of Medicine, University of Rome “Campus Bio-Medico”, 00128 Rome, Italy; (A.M.); (D.C.); (M.V.); (E.C.); (L.K.); (A.P.); (A.B.); (I.G.); (M.M.); (A.O.); (F.T.); (M.Q.); (C.S.); (L.P.D.C.); (F.S.); (R.G.); (L.N.)
Irene Genovali Rheumatology and Clinical Immunology, Department of Medicine, School of Medicine, University of Rome “Campus Bio-Medico”, 00128 Rome, Italy; (A.M.); (D.C.); (M.V.); (E.C.); (L.K.); (A.P.); (A.B.); (I.G.); (M.M.); (A.O.); (F.T.); (M.Q.); (C.S.); (L.P.D.C.); (F.S.); (R.G.); (L.N.)
Pietro Bearzi Rheumatology and Clinical Immunology, Department of Medicine, School of Medicine, University of Rome “Campus Bio-Medico”, 00128 Rome, Italy; (A.M.); (D.C.); (M.V.); (E.C.); (L.K.); (A.P.); (A.B.); (I.G.); (M.M.); (A.O.); (F.T.); (M.Q.); (C.S.); (L.P.D.C.); (F.S.); (R.G.); (L.N.)
Marco Minerba Rheumatology and Clinical Immunology, Department of Medicine, School of Medicine, University of Rome “Campus Bio-Medico”, 00128 Rome, Italy; (A.M.); (D.C.); (M.V.); (E.C.); (L.K.); (A.P.); (A.B.); (I.G.); (M.M.); (A.O.); (F.T.); (M.Q.); (C.S.); (L.P.D.C.); (F.S.); (R.G.); (L.N.)
Antonio Orlando Rheumatology and Clinical Immunology, Department of Medicine, School of Medicine, University of Rome “Campus Bio-Medico”, 00128 Rome, Italy; (A.M.); (D.C.); (M.V.); (E.C.); (L.K.); (A.P.); (A.B.); (I.G.); (M.M.); (A.O.); (F.T.); (M.Q.); (C.S.); (L.P.D.C.); (F.S.); (R.G.); (L.N.)
Francesca Trunfio Rheumatology and Clinical Immunology, Department of Medicine, School of Medicine, University of Rome “Campus Bio-Medico”, 00128 Rome, Italy; (A.M.); (D.C.); (M.V.); (E.C.); (L.K.); (A.P.); (A.B.); (I.G.); (M.M.); (A.O.); (F.T.); (M.Q.); (C.S.); (L.P.D.C.); (F.S.); (R.G.); (L.N.)
Maria Quadrini Rheumatology and Clinical Immunology, Department of Medicine, School of Medicine, University of Rome “Campus Bio-Medico”, 00128 Rome, Italy; (A.M.); (D.C.); (M.V.); (E.C.); (L.K.); (A.P.); (A.B.); (I.G.); (M.M.); (A.O.); (F.T.); (M.Q.); (C.S.); (L.P.D.C.); (F.S.); (R.G.); (L.N.)
Chiara Salvolini Rheumatology and Clinical Immunology, Department of Medicine, School of Medicine, University of Rome “Campus Bio-Medico”, 00128 Rome, Italy; (A.M.); (D.C.); (M.V.); (E.C.); (L.K.); (A.P.); (A.B.); (I.G.); (M.M.); (A.O.); (F.T.); (M.Q.); (C.S.); (L.P.D.C.); (F.S.); (R.G.); (L.N.)
Letizia Pia Di Corcia Rheumatology and Clinical Immunology, Department of Medicine, School of Medicine, University of Rome “Campus Bio-Medico”, 00128 Rome, Italy; (A.M.); (D.C.); (M.V.); (E.C.); (L.K.); (A.P.); (A.B.); (I.G.); (M.M.); (A.O.); (F.T.); (M.Q.); (C.S.); (L.P.D.C.); (F.S.); (R.G.); (L.N.)
Francesca Saracino Rheumatology and Clinical Immunology, Department of Medicine, School of Medicine, University of Rome “Campus Bio-Medico”, 00128 Rome, Italy; (A.M.); (D.C.); (M.V.); (E.C.); (L.K.); (A.P.); (A.B.); (I.G.); (M.M.); (A.O.); (F.T.); (M.Q.); (C.S.); (L.P.D.C.); (F.S.); (R.G.); (L.N.)
Roberto Giacomelli Rheumatology and Clinical Immunology, Department of Medicine, School of Medicine, University of Rome “Campus Bio-Medico”, 00128 Rome, Italy; (A.M.); (D.C.); (M.V.); (E.C.); (L.K.); (A.P.); (A.B.); (I.G.); (M.M.); (A.O.); (F.T.); (M.Q.); (C.S.); (L.P.D.C.); (F.S.); (R.G.); (L.N.) Clinical and Research Section of Rheumatology and Clinical Immunology, Fondazione Policlinico Universitario Campus Bio-Medico, 00128 Rome, Italy
Luca Navarini Rheumatology and Clinical Immunology, Department of Medicine, School of Medicine, University of Rome “Campus Bio-Medico”, 00128 Rome, Italy; (A.M.); (D.C.); (M.V.); (E.C.); (L.K.); (A.P.); (A.B.); (I.G.); (M.M.); (A.O.); (F.T.); (M.Q.); (C.S.); (L.P.D.C.); (F.S.); (R.G.); (L.N.) Clinical and Research Section of Rheumatology and Clinical Immunology, Fondazione Policlinico Universitario Campus Bio-Medico, 00128 Rome, Italy

Collapse

Sasaki T, Shitara H, Tajika T, Ichinose T, Hamano N, Kamiyama M, Yamamoto A, Kobayashi T, Takagishi K, Chikuda H. Relationship between Nontraumatic Shoulder Disorders and Neuropathic Pain: Retrospective Observational Analyses of Clinical Features and Background Factors. Anesthesiol Res Pract 2023;2023:6046746. [PMID: 37808338 PMCID: PMC10558267 DOI: 10.1155/2023/6046746] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2023] [Revised: 08/31/2023] [Accepted: 09/13/2023] [Indexed: 10/10/2023] Open

Abstract

Background

Accurate identification of neuropathic pain is necessary for appropriate treatment; however, the relationship between nontraumatic shoulder disorders and neuropathic pain remains unknown. Therefore, this retrospective observational study aimed to investigate the relationship, features, background factors, and prevalence of neuropathic pain among patients with nontraumatic shoulder disorders.

Methods

We evaluated 198 patients who visited our outpatient clinic, which specializes in shoulder disorders, from April 2015 to March 2016. The patients' age, sex, affected side, diagnosis, and pain duration were recorded, and the results of physical examination, including passive range of motion, impingement sign, and muscular strength assessments, were analyzed. The presence of neuropathic pain was assessed using the painDETECT questionnaire. Participants were divided into two groups according to the presence of neuropathic pain. Pain intensity was assessed using a visual analog scale, and the patient's mental status was assessed using the short-form McGill Pain Questionnaire and Hospital Anxiety and Depression Scale. The scores were compared between the groups.

Results

Neuropathic pain was observed in 7.6% of patients. The visual analog scale score for pain, short-form McGill Pain Questionnaire score, and Hospital Anxiety and Depression Scale score were significantly associated with the presence of neuropathic pain in the univariate analysis. Patient background factors and physical function were not associated with the presence of neuropathic pain. The prevalence of neuropathic pain in patients with frozen shoulder was 33.3%, which was significantly higher than that in patients with other shoulder disorders.

Conclusion

The occurrence of neuropathic pain may aggravate pain in patients with nontraumatic shoulder disorders. Neuropathic pain was not a rare condition in patients with nontraumatic shoulder disorders, particularly in those with frozen shoulder. The coexistence of neuropathic pain cannot be determined from background factors or physical function. Accurate diagnosis of neuropathic pain is essential in patients with nontraumatic shoulder disorders.

Collapse

Taylor PC. Pain in the joints and beyond; the challenge of rheumatoid arthritis. THE LANCET. RHEUMATOLOGY 2023;5:e351-e360. [PMID: 38251602 DOI: 10.1016/s2665-9913(23)00094-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/12/2022] [Revised: 03/13/2023] [Accepted: 03/21/2023] [Indexed: 01/23/2024]

Cheng DW, Yue YF, Chen CX, Hu YD, Tang Q, Xie M, Liu L, Li D, Zhu HL, Cheng ML. Emodin alleviates arthritis pain through reducing spinal inflammation and oxidative stress. Mol Pain 2022;18:17448069221146398. [PMID: 36474308 PMCID: PMC9772972 DOI: 10.1177/17448069221146398] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open

Abstract

Chronic pain is the predominant problem for rheumatoid arthritis patients, and negatively affects quality of life. Arthritis pain management remains largely inadequate, and developing new treatment strategies are urgently needed. Spinal inflammation and oxidative stress contribute to arthritis pain and represent ideal targets for the treatment of arthritis pain. In the present study, collagen-induced arthritis (CIA) mouse model was established by intradermally injection of type II collagen (CII) in complete Freund's adjuvant (CFA) solution, and exhibited as paw and ankle swelling, pain hypersensitivity and motor disability. In spinal cord, CIA inducement triggered spinal inflammatory reaction presenting with inflammatory cells infiltration, increased Interleukin-1β (IL-1β) expression, and up-regulated NOD-like receptor thermal protein domain associated protein 3 (NLRP3) and cleaved caspase-1 levels, elevated spinal oxidative level presenting as decreased nuclear factor E2-related factor 2 (Nrf2) expression and Superoxide dismutase (SOD) activity. To explore potential therapeutic options for arthritis pain, emodin was intraperitoneally injected for 3 days on CIA mice. Emodin treatment statistically elevated mechanical pain sensitivity, suppressed spontaneous pain, recovered motor coordination, decreased spinal inflammation score and IL-1β expression, increased spinal Nrf2 expression and SOD activity. Further, AutoDock data showed that emodin bind to Adenosine 5'-monophosphate (AMP)-activated protein kinase (AMPK) through two electrovalent bonds. And emodin treatment increased the phosphorylated AMPK at threonine 172. In summary, emodin treatment activates AMPK, suppresses NLRP3 inflammasome response, elevates antioxidant response, inhibits spinal inflammatory reaction and alleviates arthritis pain.

Collapse

Early response to JAK inhibitors on central sensitization and pain catastrophizing in patients with active rheumatoid arthritis. Inflammopharmacology 2022;30:1119-1128. [PMID: 35505266 PMCID: PMC9135884 DOI: 10.1007/s10787-022-00995-z] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2022] [Accepted: 04/09/2022] [Indexed: 12/19/2022]

Mechanisms and Mediators of Pain in Chronic Inflammatory Arthritis. CURRENT TREATMENT OPTIONS IN RHEUMATOLOGY 2021. [DOI: 10.1007/s40674-021-00178-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]

Iyer P, Lee YC. Why It Hurts: The Mechanisms of Pain in Rheumatoid Arthritis. Rheum Dis Clin North Am 2021;47:229-244. [PMID: 33781492 DOI: 10.1016/j.rdc.2020.12.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]

Buckley CD, Simón-Campos JA, Zhdan V, Becker B, Davy K, Fisheleva E, Gupta A, Hawkes C, Inman D, Layton M, Mitchell N, Patel J, Saurigny D, Williamson R, Tak PP. Efficacy, patient-reported outcomes, and safety of the anti-granulocyte macrophage colony-stimulating factor antibody otilimab (GSK3196165) in patients with rheumatoid arthritis: a randomised, phase 2b, dose-ranging study. THE LANCET. RHEUMATOLOGY 2020;2:e677-e688. [PMID: 38279364 DOI: 10.1016/s2665-9913(20)30229-0] [Citation(s) in RCA: 23] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/20/2019] [Revised: 07/02/2020] [Accepted: 07/03/2020] [Indexed: 11/29/2022]

Abstract

BACKGROUND

The human monoclonal antibody otilimab inhibits granulocyte-macrophage colony-stimulating factor (GM-CSF), a key driver in immune-mediated inflammatory conditions. We aimed to evaluate the efficacy, safety, and key patient-reported outcomes related to pain in patients with active rheumatoid arthritis receiving otilimab.

METHODS

This phase 2b, dose-ranging, multicentre, placebo-controlled study was done at 64 sites across 14 countries. Patients aged 18 years or older with rheumatoid arthritis who were receiving stable methotrexate were randomly assigned (1:1:1:1:1:1) to subcutaneous placebo or otilimab 22·5 mg, 45 mg, 90 mg, 135 mg, or 180 mg, plus methotrexate, once weekly for 5 weeks, then every other week until week 50. The randomisation schedule was generated by the sponsor, and patients were assigned to treatment by interactive response technology. Randomisation was blocked (block size of six) but was not stratified. Investigators, patients, and the sponsor were blinded to treatment. An unblinded administrator prepared and administered the study drug. The primary endpoint was the proportion of patients who achieved disease activity score for 28 joints with C-reactive protein (DAS28-CRP) <2·6 at week 24. Patients who were not in the otilimab 180 mg group, without a good or moderate European League Against Rheumatism response (week 12) or with DAS28-CRP >3·2 (week 24) escaped to otilimab 180 mg. Patients who escaped were treated as non-responders in their original assigned group. Safety endpoints were incidence of adverse events and serious adverse events, infections, and pulmonary events. Efficacy and safety outcomes were assessed in the intention-to-treat population. This study is registered with ClinicalTrials.gov, NCT02504671.

FINDINGS

Between July 23, 2015, and Dec 29, 2017, 222 patients were randomly assigned (37 to each group). 86 (49%) of 175 escaped to otilimab 180 mg at week 12 and 57 (69%) of 83 at week 24. At week 24, the proportion of patients with DAS28-CRP <2·6 was two (5%) of 37 in the otilimab 22·5 mg group, six (16%) of 37 in the 45 mg group, seven (19%) of 37 in the 90 mg group, five (14%) of 37 in the 135 mg group, five (14%) of 37 in the 180 mg, and one (3%) of 37 in the placebo group. The largest difference was achieved with otilimab 90 mg (16·2%; odds ratio [OR] 8·39, 95% CI 0·98-72·14; p=0·053). Adverse events were reported pre-escape in 19-24 (51-65%) patients and post escape in 10-17 (40-61%) patients across otilimab dose groups and in 18 (49%) of 37 and 22 (67%) of 33 in the placebo group. The most common adverse event was nasopharyngitis: 3-9 (8-24%) in otilimab groups and one (3%) in the placebo group pre-escape and 1-3 (4-10%) in otilimab groups and seven (21%) in the placebo group post escape. Pre-escape serious adverse events were foot fracture (otilimab 45 mg); arthralgia, myocardial infarction, dizziness (otilimab 90 mg); oesophageal spasm, acute pyelonephritis (otilimab 22·5 mg), and uterine leiomyoma (otilimab 135 mg). Post-escape serious adverse events were ankle fracture (placebo) and rheumatoid arthritis (otilimab 135 mg). There were no deaths or pulmonary events of clinical concern, and rates of serious infection were low.

INTERPRETATION

Otilimab plus methotrexate was well tolerated and, despite not achieving the primary endpoint of DAS28-CRP remission, there were improvements compared with placebo in disease activity scores. Of note, patients reported significant improvement in pain and physical function, supporting further clinical development of otilimab in rheumatoid arthritis.

FUNDING

GlaxoSmithKline.

Collapse

Smerilli G, Di Matteo A, Cipolletta E, Carloni S, Incorvaia A, Di Carlo M, Grassi W, Filippucci E. Ultrasound assessment of carpal tunnel in rheumatoid arthritis and idiopathic carpal tunnel syndrome. Clin Rheumatol 2020;40:1085-1092. [PMID: 32696282 PMCID: PMC7895772 DOI: 10.1007/s10067-020-05293-z] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2020] [Revised: 07/09/2020] [Accepted: 07/13/2020] [Indexed: 11/29/2022]

Abstract

Objectives

To comparatively assess the sonographic spectrum of carpal tunnel syndrome (CTS) in patients with rheumatoid arthritis (RA) and in patients with idiopathic CTS.

Methods

Fifty-seven RA patients and 25 idiopathic CTS patients were consecutively enrolled. The diagnosis of CTS in RA patients was made according to clinical history and examination. The following sonographic findings were assessed at carpal tunnel level: median nerve cross-sectional area (CSA) at the carpal tunnel proximal inlet, finger flexor tendons tenosynovitis, radio-carpal synovitis and intraneural power Doppler (PD) signal.

Results

CTS was diagnosed in 15/57 RA patients (26.3%). Twenty-three RA wrists with CTS, 84 RA wrists without CTS and 34 idiopathic CTS wrists were evaluated. The average CSA of the median nerve was higher in idiopathic CTS than in RA wrists with CTS (17.7 mm² vs 10.6 mm², p < 0.01). A higher rate of inflammation of synovial structures (flexor tendons sheath and/or radio-carpal joint) was found in RA wrists with CTS compared with those without CTS (p = 0.04) and idiopathic CTS (p = 0.02). Intraneural PD signal was more common in CTS (in both RA and idiopathic CTS) wrists compared with wrists without CTS (p < 0.01).

Conclusion

The sonographic spectrum of CTS in RA patients is characterized by an inflammatory pattern, defined by the presence of finger flexor tendons tenosynovitis and/or radio-carpal joint synovitis. Conversely, a marked median nerve swelling is the dominant feature in idiopathic CTS. Intraneural PD signal is a frequent finding in both conditions.

Key Points

• Carpal tunnel syndrome (CTS) associated with rheumatoid arthritis (RA) and idiopathic CTS have distinct ultrasound patterns.

• The most characteristic sonographic features of CTS in RA patients are those indicative of synovial tissue inflammation at carpal tunnel level. Conversely, marked median nerve swelling is the dominant finding in idiopathic CTS.

• Intraneural power Doppler signal is a frequent finding in both conditions.

• In patients with CTS, differently from electrophysiology, US can provide clues prompting a rheumatology referral in case of prominent inflammatory findings at carpal tunnel level.

Collapse

Mathieu S, Couderc M, Pereira B, Dubost JJ, Malochet-Guinamand S, Tournadre A, Soubrier M, Moisset X. Prevalence of Migraine and Neuropathic Pain in Rheumatic Diseases. J Clin Med 2020;9:jcm9061890. [PMID: 32560321 PMCID: PMC7356241 DOI: 10.3390/jcm9061890] [Citation(s) in RCA: 17] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2020] [Revised: 06/12/2020] [Accepted: 06/15/2020] [Indexed: 12/14/2022] Open

Svensson B, Forslind K, Andersson M. Unacceptable pain in the BARFOT inception cohort of patients with rheumatoid arthritis: a long-term study. Scand J Rheumatol 2020;49:371-378. [PMID: 32496838 DOI: 10.1080/03009742.2020.1729404] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]

Di Carlo M, Muto P, Benfaremo D, Luchetti MM, Atzeni F, Salaffi F. The Neuropathic Pain Features in Psoriatic Arthritis: A Cross-sectional Evaluation of Prevalence and Associated Factors. J Rheumatol 2019;47:1198-1203. [PMID: 31787602 DOI: 10.3899/jrheum.190906] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/08/2019] [Indexed: 01/14/2023]

Affiliation(s)

Marco Di Carlo From the Rheumatological Clinic, Università Politecnica delle Marche, Ospedale "C. Urbani," Jesi (Ancona); Rheumatology Unit, Policlinico Universitario "G. Martino," Università degli studi di Messina, Messina; Medical Clinic, Università Politecnica delle Marche, Ancona, Italy. .,M. Di Carlo, MD, Rheumatological Clinic, Università Politecnica delle Marche, Ospedale "C. Urbani"; P. Muto, MD, Rheumatology Unit, Policlinico Universitario "G. Martino," Università degli studi di Messina; D. Benfaremo, MD, Medical Clinic, Università Politecnica delle Marche; M.M. Luchetti, MD, Medical Clinic, Università Politecnica delle Marche; F. Atzeni, MD, Rheumatology Unit, Policlinico Universitario "G. Martino," Università degli studi di Messina; F. Salaffi, MD, PhD, Rheumatological Clinic, Università Politecnica delle Marche, Ospedale "C. Urbani."
Pietro Muto From the Rheumatological Clinic, Università Politecnica delle Marche, Ospedale "C. Urbani," Jesi (Ancona); Rheumatology Unit, Policlinico Universitario "G. Martino," Università degli studi di Messina, Messina; Medical Clinic, Università Politecnica delle Marche, Ancona, Italy.,M. Di Carlo, MD, Rheumatological Clinic, Università Politecnica delle Marche, Ospedale "C. Urbani"; P. Muto, MD, Rheumatology Unit, Policlinico Universitario "G. Martino," Università degli studi di Messina; D. Benfaremo, MD, Medical Clinic, Università Politecnica delle Marche; M.M. Luchetti, MD, Medical Clinic, Università Politecnica delle Marche; F. Atzeni, MD, Rheumatology Unit, Policlinico Universitario "G. Martino," Università degli studi di Messina; F. Salaffi, MD, PhD, Rheumatological Clinic, Università Politecnica delle Marche, Ospedale "C. Urbani."
Devis Benfaremo From the Rheumatological Clinic, Università Politecnica delle Marche, Ospedale "C. Urbani," Jesi (Ancona); Rheumatology Unit, Policlinico Universitario "G. Martino," Università degli studi di Messina, Messina; Medical Clinic, Università Politecnica delle Marche, Ancona, Italy.,M. Di Carlo, MD, Rheumatological Clinic, Università Politecnica delle Marche, Ospedale "C. Urbani"; P. Muto, MD, Rheumatology Unit, Policlinico Universitario "G. Martino," Università degli studi di Messina; D. Benfaremo, MD, Medical Clinic, Università Politecnica delle Marche; M.M. Luchetti, MD, Medical Clinic, Università Politecnica delle Marche; F. Atzeni, MD, Rheumatology Unit, Policlinico Universitario "G. Martino," Università degli studi di Messina; F. Salaffi, MD, PhD, Rheumatological Clinic, Università Politecnica delle Marche, Ospedale "C. Urbani."
Michele Maria Luchetti From the Rheumatological Clinic, Università Politecnica delle Marche, Ospedale "C. Urbani," Jesi (Ancona); Rheumatology Unit, Policlinico Universitario "G. Martino," Università degli studi di Messina, Messina; Medical Clinic, Università Politecnica delle Marche, Ancona, Italy.,M. Di Carlo, MD, Rheumatological Clinic, Università Politecnica delle Marche, Ospedale "C. Urbani"; P. Muto, MD, Rheumatology Unit, Policlinico Universitario "G. Martino," Università degli studi di Messina; D. Benfaremo, MD, Medical Clinic, Università Politecnica delle Marche; M.M. Luchetti, MD, Medical Clinic, Università Politecnica delle Marche; F. Atzeni, MD, Rheumatology Unit, Policlinico Universitario "G. Martino," Università degli studi di Messina; F. Salaffi, MD, PhD, Rheumatological Clinic, Università Politecnica delle Marche, Ospedale "C. Urbani."
Fabiola Atzeni From the Rheumatological Clinic, Università Politecnica delle Marche, Ospedale "C. Urbani," Jesi (Ancona); Rheumatology Unit, Policlinico Universitario "G. Martino," Università degli studi di Messina, Messina; Medical Clinic, Università Politecnica delle Marche, Ancona, Italy.,M. Di Carlo, MD, Rheumatological Clinic, Università Politecnica delle Marche, Ospedale "C. Urbani"; P. Muto, MD, Rheumatology Unit, Policlinico Universitario "G. Martino," Università degli studi di Messina; D. Benfaremo, MD, Medical Clinic, Università Politecnica delle Marche; M.M. Luchetti, MD, Medical Clinic, Università Politecnica delle Marche; F. Atzeni, MD, Rheumatology Unit, Policlinico Universitario "G. Martino," Università degli studi di Messina; F. Salaffi, MD, PhD, Rheumatological Clinic, Università Politecnica delle Marche, Ospedale "C. Urbani."
Fausto Salaffi From the Rheumatological Clinic, Università Politecnica delle Marche, Ospedale "C. Urbani," Jesi (Ancona); Rheumatology Unit, Policlinico Universitario "G. Martino," Università degli studi di Messina, Messina; Medical Clinic, Università Politecnica delle Marche, Ancona, Italy.,M. Di Carlo, MD, Rheumatological Clinic, Università Politecnica delle Marche, Ospedale "C. Urbani"; P. Muto, MD, Rheumatology Unit, Policlinico Universitario "G. Martino," Università degli studi di Messina; D. Benfaremo, MD, Medical Clinic, Università Politecnica delle Marche; M.M. Luchetti, MD, Medical Clinic, Università Politecnica delle Marche; F. Atzeni, MD, Rheumatology Unit, Policlinico Universitario "G. Martino," Università degli studi di Messina; F. Salaffi, MD, PhD, Rheumatological Clinic, Università Politecnica delle Marche, Ospedale "C. Urbani."

Collapse

Guler MA, Celik OF, Ayhan FF. The important role of central sensitization in chronic musculoskeletal pain seen in different rheumatic diseases. Clin Rheumatol 2019;39:269-274. [PMID: 31446538 DOI: 10.1007/s10067-019-04749-1] [Citation(s) in RCA: 38] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2019] [Revised: 07/31/2019] [Accepted: 08/12/2019] [Indexed: 01/06/2023]

Are painDETECT scores in musculoskeletal disorders associated with duration of daily pain and time elapsed since current pain onset? Pain Rep 2019;4:e739. [PMID: 31583354 PMCID: PMC6749904 DOI: 10.1097/pr9.0000000000000739] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2018] [Revised: 02/20/2019] [Accepted: 03/04/2019] [Indexed: 12/30/2022] Open